Table 5.

Multivariable association of severity of AKI and change (fold increase) in level of urine protein-to-creatinine ratio overall and analyses that exclude receipt of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or systolic BP level

Comparisons	Full Model		Model Excluding Receipt of ACE-I/ARB		Model Excluding Systolic BP Level
	Relative Risk (95% CI)	P Value	Relative Risk (95% CI)	P Value	Relative Risk (95% CI)	P Value
AKI stage 1 between study visits (versus no AKI)	1.06 (0.97 to 1.16)	0.22	1.06 (0.97 to 1.16)	0.21	1.04 (0.95 to 1.14)	0.35
AKI stage 2 between study visits (versus no AKI)	1.01 (0.89 to 1.15)	0.88	1.01 (0.88 to 1.15)	0.92	0.99 (0.87 to 1.13)	0.89
AKI stage 3 between study visits (versus no AKI)	1.24 (1.09 to 1.40)	<0.001	1.25 (1.10 to 1.42)	<0.001	1.21 (1.06 to 1.37)	<0.01

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; 95% CI, 95% confidence interval.